Progress in neoadjuvant therapy for gastric cancer.
gastric cancer
neoadjuvant chemoradiotherapy
neoadjuvant chemotherapy
targeted therapy
Journal
Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
31
12
2021
accepted:
28
03
2022
entrez:
2
5
2022
pubmed:
3
5
2022
medline:
3
5
2022
Statut:
ppublish
Résumé
Gastric cancer is one of the most common malignant tumor types in the world and the majority of patients have already reached the advanced stage at the time of initial diagnosis, owing to the subtle symptoms of gastric cancer in the early stage and the low rate of screening in the population. Surgical resection is one of the main treatments for advanced gastric cancer; however, the efficacy of surgery is limited by factors such as low radical resection rate and high distant metastasis rate. A large number of clinical trials have indicated that neoadjuvant therapy (NAT), which consists of neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy and NAT combined with targeted therapy, may improve the therapeutic effect and prognosis of patients to different degrees. However, the benefit of NAT remains controversial due to the heterogeneity of clinical trials and gastric cancer itself. The present review summarizes the main research progress and key breakthrough of NAT for advanced gastric cancer and discusses its prospects.
Identifiants
pubmed: 35497934
doi: 10.3892/ol.2022.13292
pii: OL-23-06-13292
pmc: PMC9019865
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
172Informations de copyright
Copyright: © Su et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Lancet Oncol. 2017 Mar;18(3):357-370
pubmed: 28163000
Ann Surg. 2011 May;253(5):934-9
pubmed: 21490451
J Surg Oncol. 2012 Jun 15;105(8):793-9
pubmed: 22189752
Am J Clin Oncol. 2017 Feb;40(1):17-21
pubmed: 24662266
Med Sci Monit. 2018 Jan 12;24:235-245
pubmed: 29326419
J Clin Oncol. 2010 Dec 10;28(35):5210-8
pubmed: 21060024
Ann Surg Oncol. 2017 Aug;24(8):2252-2258
pubmed: 28337660
J Gastrointest Oncol. 2015 Oct;6(5):534-43
pubmed: 26487948
Clin Proteomics. 2020 Feb 06;17:4
pubmed: 32042279
Biosci Rep. 2019 May 21;39(5):
pubmed: 30902884
J Cancer. 2019 Jun 2;10(12):2811-2821
pubmed: 31258789
Cancer Commun (Lond). 2021 Aug;41(8):747-795
pubmed: 34197702
BMC Cancer. 2019 May 24;19(1):494
pubmed: 31126258
J Clin Oncol. 2009 Feb 20;27(6):851-6
pubmed: 19139439
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Cancer. 2003 Oct 1;98(7):1521-30
pubmed: 14508841
J Cancer. 2019 Jun 2;10(14):3094-3101
pubmed: 31289579
Gastric Cancer. 2019 Sep;22(5):1044-1052
pubmed: 30827001
Ann Oncol. 2016 Sep;27(suppl 5):v38-v49
pubmed: 27664260
J BUON. 2019 Jan-Feb;24(1):201-214
pubmed: 30941971
Gastric Cancer. 2011 Jun;14(2):101-12
pubmed: 21573743
Eur J Surg Oncol. 2004 Aug;30(6):643-9
pubmed: 15256239
J Nucl Med. 2016 Jul;57(7):1040-4
pubmed: 26966162
Cancer Discov. 2019 Dec;9(12):1656-1672
pubmed: 31727671
Eur J Cancer. 1999 Apr;35(4):558-62
pubmed: 10492627
Cancer Treat Rev. 2018 Sep;69:90-100
pubmed: 29957366
J Clin Oncol. 2011 May 1;29(13):1715-21
pubmed: 21444866
World J Gastroenterol. 2015 Mar 7;21(9):2711-8
pubmed: 25759540
Cancer Gene Ther. 2021 May;28(5):390-399
pubmed: 33009508
Eur J Surg Oncol. 2017 Sep;43(9):1607-1616
pubmed: 28347525
Lancet Oncol. 2018 May;19(5):616-628
pubmed: 29650363
Lancet Oncol. 2018 May;19(5):581-583
pubmed: 29650361
J Clin Oncol. 2012 Jan 20;30(3):268-73
pubmed: 22184384
JAMA Oncol. 2019 Dec 1;5(12):1749-1768
pubmed: 31560378
J Nucl Med. 2015 Oct;56(10):1494-500
pubmed: 26251414
Gastric Cancer. 2015 Jan;18(1):168-76
pubmed: 24557418
J Clin Oncol. 2016 Aug 10;34(23):2721-7
pubmed: 27298411
N Engl J Med. 2001 Sep 6;345(10):725-30
pubmed: 11547741
Surg Today. 2020 Jan;50(1):30-37
pubmed: 31612329
Eur J Cancer. 2016 Jul;62:103-11
pubmed: 27244537
Cancer Biomark. 2018;22(1):143-149
pubmed: 29562501
Lancet Oncol. 2016 Dec;17(12):1697-1708
pubmed: 27776843
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437
Cell Res. 2016 Aug;26(8):963-6
pubmed: 27364686
Eur J Cancer. 2020 May;130:12-19
pubmed: 32171104
N Engl J Med. 2006 Jul 6;355(1):11-20
pubmed: 16822992
BMC Cancer. 2016 Feb 08;16:68
pubmed: 26857702
Lancet Oncol. 2015 Sep;16(9):1090-1098
pubmed: 26254683
Lancet Oncol. 2017 Sep;18(9):1249-1260
pubmed: 28784312
J Clin Lab Anal. 2018 May;32(4):e22363
pubmed: 29168576
Updates Surg. 2017 Mar;69(1):35-43
pubmed: 28276033
Lancet Oncol. 2021 Aug;22(8):1081-1092
pubmed: 34252374
Clin Nucl Med. 2020 Jan;45(1):38-43
pubmed: 31714278
J Clin Oncol. 2011 Oct 20;29(30):3968-76
pubmed: 21844504
Ann Oncol. 2016 Apr;27(4):660-7
pubmed: 26782957
Arch Med Sci. 2011 Apr;7(2):287-93
pubmed: 22291769
Drugs. 2020 Apr;80(5):501-508
pubmed: 32144719
Lancet. 2019 May 11;393(10184):1948-1957
pubmed: 30982686
Eur J Cancer. 2017 Aug;81:183-190
pubmed: 28628843
N Engl J Med. 2012 May 31;366(22):2074-84
pubmed: 22646630
Int J Cancer. 2021 Sep 15;149(6):1322-1331
pubmed: 34019698
Curr Treat Options Oncol. 2020 Jul 28;21(9):70
pubmed: 32725377